Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

Benzinga

Major test of first possible Lyme vaccine in 20 years begins

Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years

The Independent UK

BioNTech reports strong first half, expects demand to grow

BioNTech, which teamed with Pfizer to develop the first widely used COVID-19 vaccine, has reported higher revenue and net profit in the first half of the year

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Benzinga Before The Bell: Elon Musk Confirms Tesla AI Day Part 2, Dogecoin Scam, BioNTech Q2 Earnings Shocker And Other Top Financial Stories Monday, August 8

CNBC Celsius Withdraws Motion To Rehire CFO

Benzinga

Climate change puts Lyme disease in focus for France's Valneva after COVID blow

With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot.

Reuters

Over 1 million courses of Paxlovid prescribed in one month for first time

There were 1.26 million courses dispensed last month, a 37% increase when compared to June numbers.

Axios

Check Out What Whales Are Doing With PFE

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

How common is Paxlovid rebound as Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The Independent UK

Why the Jan. 6 hearings should be making corporations nervous

The world is watching the Jan. 6 hearings in the United States in dismay and contemplating the possible end of the American democratic experiment.

The Conversation

Who is eligible for the second COVID-19 booster?

21.2 million Americans received their second booster by the end of July.

USAFacts

Biden suffers a Paxlovid "rebound"

After taking Paxlovid, Biden tested negative for several days, then positive. He's not the only one

Salon

COVID: antiviral drugs are a vital weapon – but misusing them could backfire

The “living with COVID” strategy being pursued by many countries relies heavily on two key pillars. First, that vaccines continue to protect most people from severe disease. And second, that where they don’t, people will receive antiviral treatments. But are the antivirals currently available sufficiently effective, accessible and durable?

The Conversation

Lisa Jarvis: At last, a simple strategy for COVID booster shots

The Food and Drug Administration reportedly has a new strategy for rolling out new booster shots that should bring needed clarity to COVID vaccination in the U.S. Going forward, most Americans will get the same advice about when to get their next shots.

Tribune News Service

How common is Paxlovid rebound as Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The New Daily

The kids are all right: Fewer COVID-19 vaccine side effects

Australian children aged 5–15 years have reported fewer side effects in the days after receiving the mRNA COVID-19 vaccine than those in clinical trials.

Chicago Sun-Times

Biden tests positive for COVID-19 again, returns to isolation

White House physician Dr. Kevin O’Connor said in a letter that Biden “has experienced no reemergence of symptoms, and continues to feel quite well.”

The Guardian - UK

Andrew Hopkins of Exscientia: the man using AI to cure disease

The British scientist’s company employs artificial intelligence to drastically cut the time of drug development

Benzinga

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

Zenara Pharma gets CDSCO nod to make copy of Pfizer’s Paxlovid

Combi pack of Nirmatrelvir, Ritonavir tablets is for patients with moderate symptoms of Covid-19

The Times of India

Hyderabad-based Zenara Pharma gets CDSCO nod to manufacture generic version of Pfizer's Covid-19 pill

HYDERABAD: Hyderabad-based Zenara Pharma, a fully-owned subsidiary of Biophore India Pharmaceuticals, on Thursday said it has received emergency use authorisation (EUA) from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market in India a generic version of Pfizer’s Covid-19 pill Paxlovid for the treatment of patients with mild…

Benzinga

Check Out What Whales Are Doing With PFE

Someone with a lot of money to spend has taken a bearish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The Independent UK

What is Paxlovid? Everything you need to know about Joe Biden’s antiviral Covid drug treatment

Late-stage clinical trial found nearly 90 per cent effectiveness from antiviral pill

Los Angeles Times

Should you wait for the omicron booster? Why experts say you should 'get it now!'

If you're like most Americans, you've gotten your primary doses of a COVID-19 vaccine, but you haven't gotten the recommended booster shots. So if it's been several months since your last primary dose, you're probably due for a booster.

StockNews.com

3 High-Quality Stocks to Pick Up for the Second-Half

The bear market provides an opportunity for investors to buy shares of high-quality companies at attractive valuations. Below are 3 such stocks that investors should consider buying during this market correction: Elevance Health (ELVH), Pfizer (PFE), and Builders FirstSource (BLDR).

The Canberra Times

High number of COVID-19 hospitalisations in ACT but only one in ICU

The ACT recorded 949 new COVID-19 cases in the 24 hours until 8pm Monday.

1 … 42 43 44 45

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.